N/A
N=329
Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00937547 ↗Enrolled (actual)
329
Serious AEs
—
Results posted
Nov 2012
Primary outcome: Primary: HPV Identification — 95; 142; 78 biopsies
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- Female
- Sponsor
- Instituto Oncologico Luis Razetti
- Primary completion
- Jul 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HPV Identification |
95; 142; 78 | — |
| PRIMARY HPV Type 16 |
65; 90; 35 | — |
| PRIMARY HPV Type 18 |
11; 14; 5 | — |
| PRIMARY HPV Type 31 |
6; 10; 8 | — |
| PRIMARY HPV Type 33 |
6; 10; 5 | — |
| PRIMARY HPV Type 45 |
6; 6; 5 | — |
| PRIMARY HPV Type 58 |
3; 7; 5 | — |
| PRIMARY HPV Type 51 |
1; 5; 7 | — |
Summary
1. Hypothesis:
If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries.
2. Objectives:
Primary objective:
The objective of this investigation is to determine the presence and genotypes of HVP infection in cervical intraepithelial neoplasia grade 2/3 (CIN 2/3), and Stage I cervical epidermoid carcinoma and cervical adenocarcinoma.
Specific objectives:
To establish the presence of HPV in cervical cancer patients in Venezuela by geographic distribution.
To establish which HPV types are linked with cervical cancer in Venezuela by geographic distribution.
Eligibility Criteria
Inclusion Criteria
paraffin blocks of 329 patients with histologic diagnosis of CIN 2, CIN 3 or Stage I cervical cancer. -
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT00937547). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.